Mycophenolatmofetil Al (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Al, is an immunosuppressant presented as an oral formulation for systemic use. It is employed to reduce the risk of organ transplant rejection by inhibiting lymphocyte proliferation. GNH USA supplies Mycophenolatmofetil Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in the transplant field to suppress immune‑mediated graft injury. - Kidney transplantation: lowers the incidence of acute rejection episodes. - Liver transplantation: helps maintain graft function and reduces rejection risk. - Heart transplantation: prevents immune‑driven graft loss and supports long‑term graft survival.

Mycophenolate Mofetil may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may affect hydration. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Leukopenia or neutropenia: significant reduction in white blood cells increasing infection risk. - Severe infections: opportunistic infections such as CMV or fungal disease. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy: increased long‑term risk of certain cancers, including lymphomas.

Before initiating therapy, clinicians should evaluate baseline laboratory values and infection risk. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess renal function: adjust dosing in renal impairment. - Avoid live vaccines: immunosuppression may render live attenuated vaccines unsafe. - Review concomitant medications: avoid additive myelosuppressive agents when possible. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Azathiine: additive bone‑marrow suppression. - Cholestyramine or other bile‑acid sequestrants: markedly reduces mycophenolate absorption. - Antacids containing aluminum or magnesium: decreases oral bioavailability.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may increase mycophenolate plasma concentrations. - Fluconazole or other azole antifungals: can raise drug levels, requiring dose adjustment. - Warfarin: may affect INR, necessitating closer coagulation monitoring.